AMRUTANJAN · NSE
Amrutanjan Health Care Limited
₹493.8
+0.57% (+₹2.8)
Prev. close
₹491
Volume
19,221
Delivery %
52.7%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Amrutanjan Health Care Limited
Amrutanjan Health Care Limited manufactures, supplies, and sells ayurvedic pain balms and women hygiene products in India and internationally. It operates through OTC Products, Beverages, Women's Hygiene & Personal Care, and Others segments. The company provides pain management products comprising pain balms and roll-ons, back pain roll-ons, stick-on patch, and joint muscle sprays; dental pain gel; and decorn corn caps; hand sanitizer under the NOGerms brand name; and enerlyte and electro, and fruit and rehydration juice drinks under the Fruitnik brand name. The company also offers congestion management products that consists of cold rubs, cough syrups, nasal inhalers, and swas mints, as well as provides sanitary napkins for women. In addition, it operates a pain management center. The company was formerly known as Amrutanjan Limited and changed its name to Amrutanjan Health Care Limited in 2007. Amrutanjan Health Care Limited was founded in 1893 and is based in Chennai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Sambhu Prasad Sivalenka
Headquarters
Chennai
Employees
661
Website
amrutanjan.comExchange
View on NSE ↗Key stats
Market cap
₹1,427.09 Cr
P/E ratio (TTM)
26.4
Dividend yield
1.52%
EPS (TTM)
₹18.67
Beta (1Y · daily vs NIFTY 50)
0.47
Beta (5Y · monthly vs NIFTY 50)
1.03
Shares float
1.51 Cr
EPS · quarter ended Jun 2026
₹1.51
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.4% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹332.84 Cr | ₹405.84 Cr | ₹379.64 Cr | ₹421.23 Cr | ₹451.82 Cr | ₹502.55 Cr | |
| EBITDA | ₹86.07 Cr | ₹94.86 Cr | ₹58.93 Cr | ₹68.16 Cr | ₹75.88 Cr | ₹84.40 Cr |
| ₹61.19 Cr | ₹67.19 Cr | ₹39.83 Cr | ₹44.97 Cr | ₹50.83 Cr | ₹57.92 Cr | |
| Diluted EPS | ₹20.93 | ₹23.03 | ₹13.63 | ₹15.56 | ₹17.58 | ₹20.03 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹349.87 Cr | ₹362.09 Cr | ₹366.87 Cr | ₹421.39 Cr | ₹508.89 Cr | |
| — | ₹87.99 L | ₹90.91 L | ₹1.73 Cr | ₹2.08 Cr | ₹1.78 Cr | |
| Stockholders' equity | — | ₹265.12 Cr | ₹290.77 Cr | ₹288.49 Cr | ₹326.61 Cr | ₹370.23 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹53.17 Cr | ₹20.18 Cr | ₹27.91 Cr | ₹50.90 Cr | ₹35.97 Cr | |
| Investing cash flow | — | ₹-36.21 Cr | ₹-2.48 Cr | ₹19.17 Cr | ₹-30.97 Cr | ₹-21.23 Cr |
| — | ₹-17.67 Cr | ₹-14.03 Cr | ₹-48.27 Cr | ₹-13.49 Cr | ₹-13.62 Cr | |
| Capital expenditure | — | ₹-23.46 Cr | ₹-8.93 Cr | ₹-6.72 Cr | ₹-35.55 Cr | ₹-55.00 Cr |
| End cash position | — | — | ₹4.90 Cr | ₹3.71 Cr | ₹10.16 Cr | ₹11.27 Cr |
Operating cash flow, Change in working capital, Investing cash flow, Financing cash flow, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Mar 22–Dec 22(4Q) | Mar 23–Jun 23(2Q) | Sep 23–Dec 23(2Q) | Mar 24–Jun 24(2Q) | Sep 24–Jun 25(4Q) | Sep 25–Jun 26(4Q) |
|---|---|---|---|---|---|---|---|---|
| Promoter | 50.02% | 50.02% | 50.02% | 50.04% | 50.59% | 50.59% | 46.52% | 46.52% |
| Public | 49.88% | 49.87% | 49.80% | 49.79% | 49.23% | 49.34% | 53.44% | 53.45% |
| Employee trusts | 0.10% | 0.11% | 0.18% | 0.18% | 0.18% | 0.07% | 0.04% | 0.04% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Amrutanjan Health Care Limited | ₹1,427.09 Cr | ₹493.8 | 26.5 | 3.85 | 15.6% | 0.00 | +11.4% | -34.2% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 28
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Amrutanjan Health plans to set up 100,000 direct chemist outlets in FY27
Business Standard · 22 days ago
Quant MF raises Pfizer stake with Rs 131 cr purchase; Pari Washington buys over 2% in Amrutanjan Health...
Moneycontrol.com · 1 month ago